[1]McDonald GB, Sandmaier BM, Mielcarek M, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003—2007 versus 2013—2017 cohorts[J]. Ann Intern Med, 2020, 172:229-239. [2]Haji S, Shiratsuchi M, Takamatsu A, et al. Endothelial function testing before conditioning therapy is useful for predicting transplant-related complications after allogeneic hematopoietic cell transplantation[J]. Int J Hematol, 2023, 117:438-445. [3]Boittin FX, Beddek K, Thery H, et al. The immunosuppressant drug cyclosporin A aggravates irradiation effects in endothelial cells[J]. Biochem Biophys Res Commun, 2022, 602:127-134. [4]Mulder K, Patel AA, Kong WT, et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease[J]. Immunity, 2021, 54:1883-1900. [5]Yalcin K, Pehlivan B, Celen S, et al. Comparison of total Body irradiation-based versus chemotherapy-based conditionings for early complications of allogeneic hematopoietic stem cell transplantation in children with ALL[J]. J Pediatr Hematol Oncol, 2021, 43:266-270. [6]Link-Rachner CS, Sockel K, Schuetz C. Established and emerging treatments of skin GvHD[J]. Frontiers Immunol Vol, 2022,13:838494.doi:10.3389/fimmu.2022.838494. [7]Deschaumes C, Verneuil L, Ertault-Daneshpouy M, et al. CD95 ligand-dependant endothelial cell death initiates oral mucosa damage in a murine model of acute graft versus host disease[J]. Lab Invest, 2007, 87: 417-429. [8]Zouali H, Lemasson J, Calugareanu A, et al. RNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea[J]. Blood Adv, 2022, 6:2805-2811. [9]Lopes PDD, de Assis N, de Araújo NF, et al. COX/iNOS dependence for angiotensin-Ⅱ-induced endothelial dysfunction[J]. Peptides, 2022, 157:170863. doi:10.1016/j.peptides.2022.170863. [10]Ogasawara R, Hashimoto D, Kimura S, et al. Intestinal lymphatic endothelial cells produce R-spondin3[J]. Sci Rep, 2018, 8: 10719. doi:10.1038/s41598-018-29100-7. [11]Mertlitz S, Shi Y, Kalupa M, et al. Lymphangiogenesis is a feature of acute GVHD, and VEGFR-3 inhibition pro-tects against experimental GVHD[J]. Blood, 2017, 129: 1865-1875. [12]Gloude NJ, Khandelwal P, Luebbering N, et al. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD[J]. Blood, 2017, 130: 1259-1266. [13]Qi J, Pan T, You T. Upregulation of HIF-1α contributes to complement activation in transplantation-associated thrombotic microangiopathy[J]. Br J Haematol, 2022, 199: 603-615. [14]Özkan HA, Özkan SG. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation in adult patients: diagnosis, incidence, prophylaxis, and treatment[J]. Transfus Apher Sci, 2022, 61:103372. doi: 10.1016/j.transci.2022.103372. [15]Pereira M, Lee NT, Noonan J. Early endothelial activa-tion in a mouse model of graft vs host disease following chemotherapy[J]. Front Immunol, 2021, 12: 708554. doi: 10.3389/fimmu.2021.708554. [16]Cordes S, Mokhtari Z, Bartosova M. Endothelial damage and dysfunction in acute graft-versus-host disease[J]. Haematologica, 2021, 106: 2147-2160. [17]Gavriilaki E, Sakellari I, Anyfanti P, et al. Assessment of endothelial injury and pro-coagulant activity using circulating microvesicles in survivors of allogeneic hematopoietic cell transplantation[J]. Int J Mol Sci, 2020, 21:9768. doi:10.3390/ijms21249768. [18]Mathew NR, Vinnakota JM, Apostolova P, et al. Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia[J]. J Clin Invest, 2020, 130: 1315-1329. [19]Bonelli F, Lasagni Vitar RM, Merlo Pich FG, et al. Corneal endothelial cell reduction and increased neurokinin-1 receptor expression in a graft-versus-host disease preclini-cal model[J]. Exp Eye Res, 2022, 220:109128. doi:10.1016/j.exer.2022.109128. [20]Ranjan S, Goihl A, Kohli S, et al. Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells[J]. Nat Commun, 2017, 8:311. doi:10.1038/s41467-017-00169-4. [21]Dorrance AM, Moutuou MM, Goda C, et al. Modulating endothelial cells with EGFL7 to diminish aGVHD after allogeneic bone marrow transplantation in mice[J]. Blood Adv, 2022, 6: 2403-2408. [22]García-Bernal D, Palomo M, Martínez CM, et al. Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease[J]. J Cell Mol Med, 2020, 24: 8031-8044. [23]Zhao K, Tian Y, Wang J, et al. Fluvastatin-pretreated donor cells attenuated murine aGVHD by balancing effector T cell distribution and function under the regula-tion of KLF2[J]. Biomed Res Int, 2020, 2020:7619849. doi:10.1155/2020/7619849. [24]Bézie S, Charreau B, Vimond N, et al. Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice[J]. Blood Adv, 2019, 3: 3522-3538. [25]Wang W, Ye Y, Du Y, et al. EPC infusion ameliorates acute graft-versus-host disease-related endothelial injury after allogeneic bone marrow transplantation[J]. Front Immunol, 2022, 13:1019657. doi:10.3389/fimmu.2022.1019657. |